Showing 1401-1410 of 4271 results for "".
Meeting Minute
https://modernaesthetics.com/ma-issues-index/2017-sept-oct/meeting-minute/34228/News from recent meetings and a guide to upcoming events.Find Time for You
https://modernaesthetics.com/ma-issues-index/2017-july-aug/find-time-for-you/34242/Meeting the Insane, Unrealistic, Beautiful Expectations of the Uberized Consumer
https://modernaesthetics.com/ma-issues-index/2017-may-june/meeting-the-insane-unrealistic-beautiful-expectations-of-the-uberized-consumer/34283/Leverage technology to adapt to the everything-on-demand world where consumer needs are escalating, especially when it comes to getting a response to an online inquiry.In Focus
https://modernaesthetics.com/ma-issues-index/2017-mar-apr/in-focus/34292/When I Grow Up
https://modernaesthetics.com/ma-issues-index/2017-jan-feb/when-i-grow-up/34311/Exploring opportunities beyond traditional patient care. Pros and cons from those on the front-line.New in My Practice: Cosmeceuticals
https://modernaesthetics.com/ma-issues-index/2016-may-june/new-in-my-practice-cosmeceuticals/34387/MATV News: Facial Rejuvenation Market Growth; Aesthetic Industry Updates
https://modernaesthetics.com/series/matv-news/matv-news-facial-rejuvenation-market-growth-aesthetic-industry-updates/33415/In this edition of MATV News, from the editors of Modern Aesthetics® magazine, we cover a new report that predicts growth in the facial rejuvenation market and discuss that the FDA green lit Mentor's ATHENA breast implant trial. Also in this edition, a new oculoplastics app from Volk Eye Check and iIn Focus
https://modernaesthetics.com/ma-issues-index/2016-jan-feb/in-focus/34438/MATV News: FDA Approves Cellfina to Treat Cellulite; miraDry to Launch miraSmooth
https://modernaesthetics.com/series/matv-news/matv-news-fda-approves-cellfina-to-treat-cellulite-miradry-to-launch-mirasmooth/33419/In this edition of MATV News, from the editors of Modern Aesthetics® magazine, we review the FDA's clearance of Cellfina to treat cellulite with no loss of benefit for up to two-years as well as the new indication for miraDry for hair removal and the launch of miraSmooth. Also in this edition, FDA aAnywhere, Anytime
https://modernaesthetics.com/ma-issues-index/2015-july-aug/anywhere-anytime/34506/